

13 February 2018

Resonance Health signs off on new clinical trial

The Board of Resonance Health (ASX: RHT) is pleased to announce that the Company has received a new work order from a pharmaceutical company for an undisclosed confidential sum. This is in addition to the two previously announced trials disclosed in the 12 January 2018 ASX announcement. The new trial is scheduled to commence in the first quarter of 2018.

The total dollar value of work for the three multi-year clinical trials won this quarter amounts to an approximate aggregate sum of US \$677,000. Full payment is contingent upon the successful completion of the clinical trials.

Further updates will be provided as work progresses.

Martin Blake

Chairman RHT

For further information please contact:

Alison Laws

Chief Business Development Officer, Resonance Health

E: alisonl@resonancehealth.com P: +61 (0)8 9286 5300